BCL2 and lung cancer: Finally, the <i>in vivo</i> antitumor efficacy and the safety of ROF were assessed in an H358 xenograft mouse model.<h4>Results</h4>ROF potently inhibited lung cancer cell proliferation (IC<sub>50</sub>: 15.35-33.84 μM), migration, and invasion, while inducing G<sub>2</sub>/M phase arrest and apoptosis (increased Bax/Bcl-2 ratio).